Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

ELISA Capture^3,4 and ELISPOT Capture⁵: The purified TC11-18H10.1 antibody is useful as the capture antibody in a sandwich ELISA, when used in conjunction with the biotinylated TC11-8H4 antibody (Cat. No. 507002) as the detecting antibody and recombinant mouse IL-17 (Cat. No. 576009) as the standard.
Flow Cytometry^{2-4,7,8,11,12}: The TC11-18H10.1 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-17-producing cells within mixed cell populations.
Neutralization^6,9: The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for neutralization of mouse IL-17 bioactivity in vivo and in vitro (Cat. No. 506906).

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

1. Kennedy J, et al. 1996. J. Interferon Cytokine Res. 16:611.
2. Schubert D, et al. 2004. J. Immunol. 172:4503. (ICFC)
3. Infante-Duarte C, et al. 2000. J. Immunol. 165:6107. (ICFC, ELISA Capture)
4. Harrington LE, et al. 2005. Nature Immunol. doi:10.1038/ni1254. (ICFC, ELISA Capture)
5. Nekrasova T, et al. 2005. J. Immunol. 175:2734. (ELISPOT Capture)
6. Yen D, et al. 2006. J. Clin. Invest. 116:1310. (Neut)
7. Ehirchiou D, et al. 2007. J. Exp. Med. 204:1519. (ICFC)
8. Kang SG, et al. 2007. J. Immunol. 179:3724. (ICFC)
9. Smith E, et al. 2008. J. Immunol. 181:1357. (Neut) PubMed
10. Neufert C, et al. 2007. Eur. J. Immunol. 37:1809. PubMed
11. Wang C, et al. 2009. Mucosal Immunol 2:173. (ICFC) PubMed
12. Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (ICFC) PubMed
13. Kivis?kk P, et al. 2009. Ann. Neurol. 65:457. PubMed
14. Cooney LA, et al. 2011. J. Immunol. 187:4440. PubMed
15. Ma Y, et al. 2012. PLoS One. 7:e40763. PubMed
16. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed

1. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
2. Li B, et al. 2015. Sci Rep. 5: 14793. PubMed
3. Cao W, et al. 2017. Immunity. 47:1182. PubMed
4. Namai F, et al. 2020. Exp Mol Med. 52:1627. PubMed
5. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
6. Sawant D, et al. 2014. J Immunol. 192:2904. PubMed
7. Peelen E, et al. 2013. J Neuroimmunol. 258:77. PubMed
8. Kajikawa A, et al. 2012. Clin Vaccine Immunol. 19:1374. PubMed
9. Duan H, et al. 2021. J Clin Invest. 131:. PubMed
10. Saigusa R, et al. 2018. Arthritis Res Ther. 20:23. PubMed
11. Chen F, et al. 2016. J Immunol. 196: 4390 - 4399. PubMed
12. Gorman JA, et al. 2019. Front Immunol. 10:44. PubMed
13. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
14. Baja?a S, et al. 2022. iScience. 25:103732. PubMed
15. Voigt A, et al. 2015. Biol Open. 10.1242/bio.013771. PubMed
16. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
17. Huang LH et al. 2018. Cell metabolism. 29(2):475-487 . PubMed

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Numasaki M, et al. 2002. Blood 101:2620.
3. Fossiez F, et al. 1996. J. Exp. Med. 183:2593.
4. Yao Z, et al. 1997. Cytokine 9:794.
5. Dong C. 2006. Nat. Rev. Immunol. 6:329.
6. Hofstetter HH, et al. 2005 Cell. Immunol. 237:123.